WO2024254461A3 - Procédés et compositions pour le développement et la distribution de vaccins - Google Patents

Procédés et compositions pour le développement et la distribution de vaccins Download PDF

Info

Publication number
WO2024254461A3
WO2024254461A3 PCT/US2024/033024 US2024033024W WO2024254461A3 WO 2024254461 A3 WO2024254461 A3 WO 2024254461A3 US 2024033024 W US2024033024 W US 2024033024W WO 2024254461 A3 WO2024254461 A3 WO 2024254461A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
delivery
vaccine development
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033024
Other languages
English (en)
Other versions
WO2024254461A2 (fr
Inventor
Hiep Vu
The Nhu NGUYEN
Sarah SILLMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NuTech Ventures Inc
Original Assignee
NuTech Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuTech Ventures Inc filed Critical NuTech Ventures Inc
Publication of WO2024254461A2 publication Critical patent/WO2024254461A2/fr
Publication of WO2024254461A3 publication Critical patent/WO2024254461A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ce document décrit des procédés et des compositions qui peuvent être utilisés pour développer et administrer rapidement de nouveaux vaccins.
PCT/US2024/033024 2023-06-07 2024-06-07 Procédés et compositions pour le développement et la distribution de vaccins Ceased WO2024254461A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471614P 2023-06-07 2023-06-07
US63/471,614 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254461A2 WO2024254461A2 (fr) 2024-12-12
WO2024254461A3 true WO2024254461A3 (fr) 2025-01-09

Family

ID=93794636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033024 Ceased WO2024254461A2 (fr) 2023-06-07 2024-06-07 Procédés et compositions pour le développement et la distribution de vaccins

Country Status (1)

Country Link
WO (1) WO2024254461A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196806A1 (en) * 2018-05-23 2021-07-01 Gritstone Oncology, Inc. Shared antigens
US20210252133A1 (en) * 2018-08-17 2021-08-19 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US20220106257A1 (en) * 2020-07-16 2022-04-07 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022173730A1 (fr) * 2021-02-09 2022-08-18 Virginia Commonwealth University Thérapies et vaccins à base de mini-arn circulaire et leurs procédés d'utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196806A1 (en) * 2018-05-23 2021-07-01 Gritstone Oncology, Inc. Shared antigens
US20210252133A1 (en) * 2018-08-17 2021-08-19 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US20220106257A1 (en) * 2020-07-16 2022-04-07 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022173730A1 (fr) * 2021-02-09 2022-08-18 Virginia Commonwealth University Thérapies et vaccins à base de mini-arn circulaire et leurs procédés d'utilisation

Also Published As

Publication number Publication date
WO2024254461A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
EP4110383A4 (fr) Compositions et méthodes de vaccination mucosale contre le sars-cov-2
EP3725328A3 (fr) Nouvelles compositions d'adjuvants
EP4494650A3 (fr) Compositions vaccinales ayant une stabilite et une immunogenicite ameliorees
WO2013006842A3 (fr) Compositions immunogènes et leurs utilisations
WO2015120110A3 (fr) Nouvelles formulations pharmaceutiques
TW200806316A (en) Yeast-based vaccine for inducing an immune response
EP4241850A3 (fr) Inhibiteurs de mdm2 et combinaisons de ceux-ci
SA517390550B1 (ar) وحدة جرعة قابلة للتفتت في الفم تتضمن مكون أستيترول
EP4461369A3 (fr) Compositions en aérosol comprenant des mitochondries et leurs méthodes d'utilisation
EP4335851A3 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
PH12019500330A1 (en) Porcine epidemic diarrhea preventative or therapeutic method, vaccine, and vaccine kit
EP4248992A3 (fr) Vaccin contre la fièvre aphteuse
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AU2019366996A8 (en) Polymer-lipids and compositions
EP3000464A3 (fr) Composition comprenant du farnésol et son utilisation
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
WO2020012428A8 (fr) Nouveaux vaccins contre les réovirus aviaires
ZA202104747B (en) Novel trypanosomal vaccine
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
WO2024254461A3 (fr) Procédés et compositions pour le développement et la distribution de vaccins
AU2018347511A8 (en) Periodontitis vaccine and related compositions and method of use
ZA202104746B (en) Novel trypanosomal vaccine
EP4165075A4 (fr) Compositions de vaccin contre le vih, procédés et utilisations associées
WO2005056769A3 (fr) Vaccins a souche de bacterie vivante administres par voie orale contre la peste

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE